The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype

被引：0

作者：

Kenjiro Aogi

Masayuki Yoshida

Yoshiaki Sagara

Shunji Kamigaki

Minoru Okazaki

Jumpei Funai

Toshio Fujimoto

Masakazu Toi

Toshiaki Saeki

Shigemitsu Takashima

机构：

[1] Shikoku Cancer Center,Department of Breast Oncology

[2] Seirei Hamamatsu General Hospital,Department of Breast Surgery

[3] Sagara Hospital,Division of Breast Surgery

[4] Sakai Municipal Hospital,Department of Surgery

[5] Sapporo Breast Surgical Clinic,Science Communications

[6] Eli Lilly Japan K.K.,Medical Science

[7] Eli Lilly Japan K.K.,Department of Surgery

[8] Kyoto University Graduate School of Medicine,Department of Breast Oncology

[9] Saitama Medical University International Medical Center,undefined

[10] Shikoku Cancer Center,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2011年 / 67卷

关键词：

Anthracycline-pretreated metastatic breast cancer; Triple negative; Gemcitabine; Paclitaxel; Phase I/II trial;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1007 / 1015

页数：8

共 50 条

[1] The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype
Aogi, Kenjiro
Yoshida, Masayuki
Sagara, Yoshiaki
Kamigaki, Shunji
Okazaki, Minoru
Funai, Jumpei
Fujimoto, Toshio
Toi, Masakazu
Saeki, Toshiaki
Takashima, Shigemitsu
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (05) : 1007 - 1015
[2] Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Schmid, Peter
Abraham, Jacinta
Chan, Stephen
Wheatley, Duncan
Brunt, Adrian Murray
Nemsadze, Gia
Baird, Richard D.
Park, Yeon Hee
Hall, Peter S.
Perren, Timothy
Stein, Robert C.
Mangel, Laszlo
Ferrero, Jean-Marc
Phillips, Melissa
Conibear, John
Cortes, Javier
Foxley, Andrew
de Bruin, Elza C.
McEwen, Robert
Stetson, Daniel
Dougherty, Brian
Sarker, Shah-Jalal
Prendergast, Aaron
McLaughlin-Callan, Max
Burgess, Matthew
Lawrence, Cheryl
Cartwright, Hayley
Mousa, Kelly
Turner, Nicholas C.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
[3] COLET: A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib in combination with paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer
Kim, S-B
Miles, D.
Rhee, J.
Yan, Y.
Hsu, J.
Brufsky, A.
CANCER RESEARCH, 2016, 76
[4] Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: Prclineinary results report of a phase II trial
Wang, Z.
Hu, X.
Chen, L.
Wang, J.
Wang, H.
Wang, L.
Liu, G.
Hu, Z.
Wu, J.
Zhimin, S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[5] Efficacy and safety of first-line atezolizumab plus bevacizumab plus paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
Gion, Maria
Cortez-Castedo, Patricia
Blancas, Isabel
Cortes, Alfonso
Marme, Frederik
Blanch, Salvador
Murillo, Serafin Morales
Diaz, Nieves
Calvo-Plaza, Isabel
Recalde, Sabela
Martinez-Bueno, Alejandro
Ruiz-Borrego, Manuel
Llabres, Elisenda
Taberner, Maria Teresa
de Laurentiis, Michelino
Garcia-Saenz, Jose Angel
Repkova, Jana
Anton, Antonio
Gligorov, Joseph
de la Cruz, Susana
Hoffmann, Oliver
Medioni, Jacques
Phillips, Melissa
Sampayo-Cordero, Miguel
Alcala-Lopez, Daniel
Perez-Garcia, Jose Manuel
Llombart-Cussac, Antonio
Cortes, Javier
CANCER RESEARCH, 2024, 84 (09)
[6] nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
Yardley, D. A.
Coleman, R.
Conte, P.
Cortes, J.
Brufsky, A.
Shtivelband, M.
Young, R.
Bengala, C.
Ali, H.
Eakel, J.
Schneeweiss, A.
de la Cruz-Merino, L.
Wilks, S.
O'Shaughnessy, J.
Gluck, S.
Li, H.
Miller, J.
Barton, D.
Harbeck, N.
ANNALS OF ONCOLOGY, 2018, 29 (08) : 1763 - 1770
[7] Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison
Lobefaro, Riccardo
Mariani, Luigi
Peverelli, Giorgia
Ligorio, Francesca
Fuca, Giovanni
Rametta, Alessandro
Zattarin, Emma
Leporati, Rita
Presti, Daniele
Cantarelli, Beatrice
Depretto, Catherine
Vingiani, Andrea
Manoukian, Siranoush
Scaperrotta, Gianfranco
V. Bianchi, Giulia
Capri, Giuseppe
Pruneri, Giancarlo
de Braud, Filippo
Vernieri, Claudio
CLINICAL BREAST CANCER, 2023, 23 (03) : e151 - e162
[8] Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer
Zhang, J.
Lin, Y.
Sun, X. J.
Wang, B. Y.
Wang, Z. H.
Luo, J. F.
Wang, L. P.
Zhang, S.
Cao, J.
Tao, Z. H.
Wu, J.
Shao, Z. M.
Yang, W. T.
Hu, X. C.
ANNALS OF ONCOLOGY, 2018, 29 (08) : 1741 - 1747
[9] Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients
Pecora, I.
Vivaldi, C.
Rovesti, G.
Catanese, S.
Salani, F.
Gardini, A. Casadei
Massa, V.
Bernardini, L.
Riggi, M.
Andrikou, K.
Rapposelli, I.
Formica, V.
Cesario, S.
Caccese, M.
Lencioni, M.
Vasile, E.
Falcone, A.
Fornaro, L.
ANNALS OF ONCOLOGY, 2020, 31 : S151 - S151
[10] Gemcitabine with cisplatin or paclitaxel in metastatic triple-negative breast cancer
Hu, Xichun
Xu, Binghe
Cai, Li
Wang, Zhonghua
Wang, Biyun
Zhang, Jian
Teng, Yuee
Tong, Zhongsheng
Pan, Yueyin
Yin, Yongmei
Wu, Changping
Jiang, Zefei
Wang, Xiaojia
Lou, Guyin
Liu, Donggeng
Feng, Jifeng
Luo, Jianfeng
Wu, Jiong
Shao, Zhimin
Ragaz, Joseph
CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 →